Journal Article
. 2020 Sep;54().
doi: 10.1016/j.breast.2020.09.003.

Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis

Hong-Fei Gao 1 Wei-Ping Li 2 Teng Zhu 1 Ci-Qiu Yang 1 Mei Yang 1 Liu-Lu Zhang 1 Fei Ji 1 Min-Yi Cheng 1 Jie-Qing Li 1 Kun Wang 3 
Affiliations
  • PMID: 32947149
  •     20 References

Abstract

Purpose: The aim of this study was to explore the value of adjuvant chemotherapy in patients with early-stage ER/PR-positive mucinous carcinoma.

Methods: We identified early-stage ER/PR-positive mucinous carcinoma patients in the Surveillance, Epidemiology, and End Results (SEER) database. We used propensity-score matching (PSM) analysis to eliminate selection bias and differences in baseline characteristics. Univariate and multivariate analyses were performed to identify significant prognostic factors. The primary outcomes were overall survival (OS) and breast cancer-specific survival (BCSS), which were evaluated with the Kaplan-Meier method.

Results: After propensity score matching, 805 pairs were selected. Patients with early-stage ER/PR-positive mucinous adenocarcinoma in the chemotherapy group had a better OS, but not BCSS, than those in the nonchemotherapy group after PSM (OS: p < 0.001; BCSS: p = 0.285). After stratifying by tumor size and lymph node status, adjuvant chemotherapy could significantly improve the OS of early-stage ER/PR-positive patients with tumors larger than 3 cm (p = 0.004) if they had negative lymph nodes (LNs). For patients positive LNs, the OS was significantly different between the chemotherapy group and the non-chemotherapy group when the tumors were larger than 1 cm (T = 1-2.9 cm, p = 0.006; T>3 cm, p = 0.049, respectively).

Conclusion: Adjuvant chemotherapy maybe improves prognosis in patients with negative LNs and tumors larger than 3 cm, or patients with LNs metastasis and tumors larger than 1 cm. We suggest considering clinical characteristics meanwhile when deciding chemotherapy or not. Randomized controlled trials (RCT) are expected to confirm our results in the future.

Keywords: Adjuvant chemotherapy; And end results (SEER); Breast cancer; Mucinous adenocarcinomas; Overall survival; Surveillance epidemiology.

Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
A-Yong Cao, Min He, +6 authors, Zhi-Ming Shao.
Ann Surg Oncol, 2012 Mar 28; 19(9). PMID: 22451233
Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.
Jianfei Fu, Lunpo Wu, +5 authors, Shuguang Li.
PLoS One, 2016 Oct 21; 11(10). PMID: 27760180    Free PMC article.
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.
Peter C Austin.
Stat Med, 2009 Sep 17; 28(25). PMID: 19757444    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?
Ray M Merrill, Kirk A Dearden.
Cancer Causes Control, 2005 Apr 02; 15(10). PMID: 15801487
Tubular and mucinous breast cancer: results of a cohort of 917 patients.
Pauline Roux, Sophie Knight, +11 authors, Gilles Houvenaeghel.
Tumori, 2019 Mar 23; 105(1). PMID: 30900967
Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer.
Xenia Elena Bacinschi, Rodica Maricela Anghel, +3 authors, Silvia Mihaela Ilie.
Cancer Manag Res, 2020 Mar 13; 12. PMID: 32161494    Free PMC article.
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.
S G Diab, G M Clark, +3 authors, R M Elledge.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334529
Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study.
Lei Lei, Xingfei Yu, +2 authors, Xiaojia Wang.
PLoS One, 2016 May 28; 11(5). PMID: 27232881    Free PMC article.
A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Salomone Di Saverio, Juan Gutierrez, Eli Avisar.
Breast Cancer Res Treat, 2007 Nov 21; 111(3). PMID: 18026874
Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society.
Hyung Suk Kim, Jong Uk Lee, +4 authors, Woo Chan Park.
J Breast Cancer, 2020 Jan 04; 22(4). PMID: 31897333    Free PMC article.
Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands.
Marieke W J Louwman, Martine Vriezen, +5 authors, Jan Willem W Coebergh.
Int J Cancer, 2007 Mar 03; 121(1). PMID: 17330844
Propensity score estimation with boosted regression for evaluating causal effects in observational studies.
Daniel F McCaffrey, Greg Ridgeway, Andrew R Morral.
Psychol Methods, 2004 Dec 16; 9(4). PMID: 15598095
Highly Cited.
Mucoid breast carcinomas: histology and prognosis.
I S Fentiman, R R Millis, +2 authors, O Lampejo.
Br J Cancer, 1997 Jan 01; 75(7). PMID: 9083343    Free PMC article.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database.
Yongfeng Li, Meng Chen, +3 authors, George A Calin.
J Transl Med, 2019 Sep 25; 17(1). PMID: 31547814    Free PMC article.
Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC).
Rosemarie Didonato, Nella Shapiro, +3 authors, Susan Fineberg.
Histopathology, 2017 Dec 09; 72(6). PMID: 29220097
High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Torsten O Nielsen, Maj-Brit Jensen, +4 authors, Bent Ejlertsen.
Clin Cancer Res, 2016 Sep 08; 23(4). PMID: 27601592
Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Sung-Chan Gwark, Han Shin Lee, +14 authors, Jong Won Lee.
Ann Surg Oncol, 2019 Apr 13; 26(7). PMID: 30977015
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Therese B Bevers, Mark Helvie, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2018 Nov 18; 16(11). PMID: 30442736
Highly Cited.